Undifferentiated Symptoms — MCQs
On this page
A 61-year-old woman presents with a 13-week history of fatigue and unintentional 9kg weight loss. She reports increased thirst and urinary frequency. Blood tests show: glucose 18.2 mmol/L, HbA1c 98 mmol/mol, creatinine 145 μmol/L (baseline 78 μmol/L 6 months ago), eGFR 34 ml/min/1.73m² (previously 68). Urinalysis shows glucose 3+, ketones 1+, protein 2+. Blood pressure is 168/96 mmHg. What is the most appropriate initial management approach?
A 43-year-old man with poorly controlled type 2 diabetes presents with a 9-week history of severe, burning pain in both feet, rated 7/10, worse at night. The pain is interfering with sleep and daily activities. Examination shows reduced vibration sense and absent ankle reflexes bilaterally. HbA1c is 86 mmol/mol (normal <42). He has tried paracetamol without benefit. What is the most appropriate first-line pharmacological treatment?
Which of the following clinical features most reliably distinguishes systemic inflammatory conditions from localized infections as a cause of fever of unknown origin in primary care assessment?
A 24-year-old medical student presents with a 7-week history of persistent fatigue, difficulty concentrating, and feeling overwhelmed. She reports poor sleep quality, waking unrefreshed, and has gained 4kg. She denies low mood but feels constantly tired despite sleeping 9 hours nightly. Examination is unremarkable. Blood tests show TSH 6.8 mU/L (normal 0.4-4.0), free T4 12 pmol/L (normal 9-25). What is the most appropriate management?
A 59-year-old woman presents with a 5-month history of unintentional weight loss of 8kg and increasing fatigue. She reports early satiety and occasional epigastric discomfort. Physical examination reveals left supraclavicular lymphadenopathy. Abdominal examination shows mild epigastric tenderness. Blood tests show Hb 98 g/L (normal 115-165), MCV 76 fL (normal 80-100), and albumin 32 g/L (normal 35-50). What is the most appropriate next step in management?
A 44-year-old woman presents with a 17-week history of fatigue and generalised pain. She scores 8/10 for pain on average. She reports cognitive difficulties ('brain fog'), poor sleep, and irritable bowel symptoms. Physical examination including joint and neurological assessment is normal. Blood tests including FBC, ESR, CRP, thyroid function, vitamin D, and calcium are normal. She has tried several analgesics without benefit. What is the single most important component of effective management according to current UK guidelines?
A 54-year-old man presents with a 10-week history of pain in his lower back and hips. The pain is worse in the morning, improves with activity, and is associated with stiffness lasting 90 minutes. He wakes at night with pain and stiffness. NSAIDs provide good relief. Examination shows reduced lumbar spine flexion. Blood tests show ESR 58 mm/hr, CRP 42 mg/L, normal FBC and renal function. X-ray of spine and pelvis is reported as normal. What is the most appropriate next investigation?
A 48-year-old man presents with a 15-week history of fatigue, night sweats, and 8kg weight loss. Examination reveals non-tender cervical and axillary lymphadenopathy. Blood tests show Hb 102 g/L, WCC 18.5 × 10⁹/L (lymphocytes 14.2 × 10⁹/L), platelets 145 × 10⁹/L, ESR 45 mm/hr, LDH 520 U/L. Blood film shows mature small lymphocytes with smudge cells. What is the most likely diagnosis?
A 67-year-old woman presents with a 13-week history of unintentional weight loss (9kg) and progressive fatigue. She has noted increased thirst and urinary frequency. Blood tests show glucose 18.2 mmol/L, HbA1c 72 mmol/mol, C-peptide <50 pmol/L (low), and GAD antibodies strongly positive. She has no personal or family history of autoimmune disease. What is the most appropriate initial management?
A 55-year-old woman with chronic kidney disease stage 4 presents with worsening fatigue and generalised bone pain over 8 weeks. Blood tests show corrected calcium 2.15 mmol/L, phosphate 1.95 mmol/L, PTH 185 pg/mL (normal 15-65), ALP 245 U/L, and 25-hydroxyvitamin D 22 nmol/L. Hb 96 g/L, ferritin 45 μg/L. Which intervention should be prioritised first?
Undifferentiated Symptoms UK Medical PG Practice Questions and MCQs
Question 91: A 61-year-old woman presents with a 13-week history of fatigue and unintentional 9kg weight loss. She reports increased thirst and urinary frequency. Blood tests show: glucose 18.2 mmol/L, HbA1c 98 mmol/mol, creatinine 145 μmol/L (baseline 78 μmol/L 6 months ago), eGFR 34 ml/min/1.73m² (previously 68). Urinalysis shows glucose 3+, ketones 1+, protein 2+. Blood pressure is 168/96 mmHg. What is the most appropriate initial management approach?
- A. Start metformin 500mg twice daily with lifestyle advice and review in 2 weeks
- B. Admit urgently to hospital for assessment of possible diabetic ketoacidosis
- C. Start insulin therapy as outpatient with diabetes specialist nurse support within 24 hours (Correct Answer)
- D. Refer routinely to diabetes specialist team and commence lifestyle measures
- E. Start gliclazide 40mg once daily and arrange diabetes education programme
Explanation: ***Start insulin therapy as outpatient with diabetes specialist nurse support within 24 hours*** - The patient presents with **marked weight loss**, **osmotic symptoms**, and **ketonuria (1+)**, indicating a state of significant **insulin deficiency** that requires urgent management. - **Insulin therapy** is indicated at the time of diagnosis for patients with Type 2 Diabetes who exhibit severe hyperglycemia and significant metabolic decompensation without evidence of life-threatening acidosis. *Start metformin 500mg twice daily with lifestyle advice and review in 2 weeks* - **Metformin** is contraindicated in this patient as her **eGFR (34 ml/min/1.73m²)** is below the safe threshold of 45-30 ml/min for initiation. - Given the severe metabolic symptoms and high **HbA1c**, metformin mono-therapy would be inadequate to achieve rapid glycemic control. *Admit urgently to hospital for assessment of possible diabetic ketoacidosis* - **Diabetic Ketoacidosis (DKA)** typically involves significant ketosis (usually ≥2+ on urine or ≥3.0 mmol/L blood) and clinical symptoms of **acidosis** such as vomiting or Kussmaul breathing, which are not present here. - While the patient has metabolic decompensation, **1+ ketones** in an otherwise hemodynamically stable patient can often be managed safely in the community with urgent specialist support. *Refer routinely to diabetes specialist team and commence lifestyle measures* - **Routine referral** is inappropriate due to the risk of rapid clinical deterioration given the patient's significant **unintentional weight loss** and severe hyperglycemia. - Relying solely on **lifestyle measures** would be insufficient and dangerous in the presence of existing metabolic decompensation and ketonuria. *Start gliclazide 40mg once daily and arrange diabetes education programme* - **Gliclazide** (a sulfonylurea) carries a high risk of **hypoglycemia** in patients with deteriorating renal function (AKI indicated by the drop in eGFR). - **Sulfonylureas** are generally less effective and less appropriate than insulin for a patient presenting with clear signs of insulin exhaustion and ketosis.
Question 92: A 43-year-old man with poorly controlled type 2 diabetes presents with a 9-week history of severe, burning pain in both feet, rated 7/10, worse at night. The pain is interfering with sleep and daily activities. Examination shows reduced vibration sense and absent ankle reflexes bilaterally. HbA1c is 86 mmol/mol (normal <42). He has tried paracetamol without benefit. What is the most appropriate first-line pharmacological treatment?
- A. Amitriptyline 10mg at night, titrating up to 75mg as tolerated
- B. Codeine phosphate 30-60mg four times daily as required
- C. Pregabalin 75mg twice daily, titrating up to 300mg twice daily
- D. Duloxetine 60mg once daily in the morning (Correct Answer)
- E. Tramadol 50mg four times daily with regular review
Explanation: ***Duloxetine 60mg once daily in the morning*** - **Duloxetine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)** and is recommended as a first-line pharmacological treatment for **painful diabetic neuropathy** according to major guidelines. - It can be started at a therapeutic dose of 60mg once daily, offering a simpler regimen and often better adherence compared to medications requiring slow titration. *Amitriptyline 10mg at night, titrating up to 75mg as tolerated* - While **tricyclic antidepressants (TCAs)** like amitriptyline are effective first-line agents for neuropathic pain, the starting dose of 10mg is very low and may delay therapeutic benefit for severe pain. - Higher doses (e.g., 75mg) are associated with significant **anticholinergic side effects** such as dry mouth, constipation, sedation, and urinary retention, which can be problematic, especially in older diabetic patients. *Codeine phosphate 30-60mg four times daily as required* - **Opioids** are generally not recommended for the long-term management of **chronic neuropathic pain** due to limited efficacy, high risk of dependence, and significant side effects. - Codeine specifically carries a risk of **dependence**, tolerance, and common side effects like severe **constipation** and nausea, which are unsuitable for first-line chronic pain management. *Pregabalin 75mg twice daily, titrating up to 300mg twice daily* - **Pregabalin** is also a valid first-line option for neuropathic pain; however, it typically requires a **twice-daily dosing** schedule and careful **titration** over several weeks to reach an effective dose. - Common side effects include **dizziness**, somnolence, peripheral edema, and weight gain, which might be less desirable or require closer monitoring in patients with diabetes. *Tramadol 50mg four times daily with regular review* - **Tramadol** is a weak opioid and SNRI that should be considered as a second or third-line agent, or for short-term 'rescue' for acute exacerbations, not as a standard first-line long-term therapy for chronic neuropathic pain. - It carries risks of **addiction**, **serotonin syndrome** if co-administered with other serotonergic drugs, and common opioid side effects.
Question 93: Which of the following clinical features most reliably distinguishes systemic inflammatory conditions from localized infections as a cause of fever of unknown origin in primary care assessment?
- A. Fever pattern showing regular daily spikes above 39°C
- B. Presence of elevated inflammatory markers (CRP >100 mg/L)
- C. Multiple organ system involvement with no identifiable focus of infection (Correct Answer)
- D. Duration of fever exceeding 3 weeks despite investigation
- E. Absence of response to empirical broad-spectrum antibiotics
Explanation: ***Multiple organ system involvement with no identifiable focus of infection*** - **Systemic inflammatory conditions** are characterized by clinical manifestations across several domains, such as **arthralgia**, **rashes**, or **serositis**, without a localized anatomical nidus. - Localized infections typically present with symptoms limited to a **specific anatomical site**, whereas multi-system involvement in the absence of an identifiable source is highly indicative of **autoimmune** or **vasculitic** processes. *Fever pattern showing regular daily spikes above 39°C* - While some conditions like **Adult-Onset Still’s Disease** exhibit daily spikes, fever patterns are generally considered **non-specific** for distinguishing between infection and inflammation. - Modern clinical practice has found that most classic fever curves lack the **sensitivity** or **specificity** to reliably confirm a diagnosis without other clinical evidence. *Presence of elevated inflammatory markers (CRP >100 mg/L)* - Significant elevation of **C-Reactive Protein (CRP)** is a hallmark of both **acute bacterial infections** and systemic inflammatory states like **vasculitis**. - Because inflammatory markers are **non-specific acute phase reactants**, they cannot be used to reliably differentiate between the two categories of disease. *Duration of fever exceeding 3 weeks despite investigation* - A duration of over **3 weeks** is a core component of the standard definition of **Fever of Unknown Origin (FUO)** but does not help categorize the etiology. - Both **occult infections** (like Tuberculosis or deep-seated abscesses) and **connective tissue diseases** can persist for several weeks or months. *Absence of response to empirical broad-spectrum antibiotics* - Failure to respond to antibiotics can suggest a **non-infectious cause**, but it is not definitive as many infections (e.g., **resistant bacteria**, **fungi**, or **tuberculosis**) also fail standard regimens. - Empirical antibiotic use is generally discouraged in FUO as it can mask symptoms and **delay the diagnosis** of both infectious and inflammatory conditions.
Question 94: A 24-year-old medical student presents with a 7-week history of persistent fatigue, difficulty concentrating, and feeling overwhelmed. She reports poor sleep quality, waking unrefreshed, and has gained 4kg. She denies low mood but feels constantly tired despite sleeping 9 hours nightly. Examination is unremarkable. Blood tests show TSH 6.8 mU/L (normal 0.4-4.0), free T4 12 pmol/L (normal 9-25). What is the most appropriate management?
- A. Repeat thyroid function tests in 3 months with clinical review
- B. Commence levothyroxine 50 micrograms daily
- C. Request thyroid peroxidase antibodies and commence treatment if positive (Correct Answer)
- D. Reassure and advise on sleep hygiene measures only
- E. Refer to endocrinology for specialist assessment
Explanation: ***Request thyroid peroxidase antibodies and commence treatment if positive***- The patient presents with **subclinical hypothyroidism** (elevated TSH 6.8 mU/L with normal free T4 12 pmol/L) and symptoms such as **persistent fatigue**, difficulty concentrating, and weight gain; checking **thyroid peroxidase (TPO) antibodies** helps determine the autoimmune etiology and risk of progression to overt hypothyroidism.- According to **NICE guidelines**, treatment with **levothyroxine** should be considered for patients under 65 with a TSH between 4–10 mU/L if they are **symptomatic** and test positive for **TPO antibodies**, as this indicates a higher likelihood of benefit from treatment.*Repeat thyroid function tests in 3 months with clinical review*- While repeating tests is a standard approach for **asymptomatic subclinical hypothyroidism**, this patient is clearly **symptomatic** (fatigue, difficulty concentrating, weight gain), indicating a need for more proactive investigation.- Delaying further diagnostic steps, such as **TPO antibody testing**, for 3 months might prolong the patient's distressing symptoms and impact her quality of life and academic performance.*Commence levothyroxine 50 micrograms daily*- Commencing **levothyroxine** immediately for subclinical hypothyroidism with a TSH of 6.8 mU/L is generally not recommended without further investigation, particularly **TPO antibody status**.- Treatment is typically reserved for TSH levels **>10 mU/L** or lower TSH levels (4-10 mU/L) in **symptomatic** patients with confirmed **TPO antibody positivity**, as per guidelines.*Reassure and advise on sleep hygiene measures only*- Although the patient reports poor sleep, her symptoms of **persistent fatigue** and **weight gain**, coupled with the **elevated TSH**, indicate an underlying physiological cause beyond simple lifestyle factors or poor sleep hygiene.- Reassurance alone would ignore the biochemical evidence of **thyroid dysfunction** and the potential for effective treatment to alleviate her symptoms.*Refer to endocrinology for specialist assessment*- Initial investigation and management of **subclinical hypothyroidism**, especially with TSH levels below 10 mU/L, can typically be managed in **primary care**.- Referral to endocrinology is usually reserved for complex cases, **pregnant women**, or when there are diagnostic ambiguities or difficulties in managing treatment.
Question 95: A 59-year-old woman presents with a 5-month history of unintentional weight loss of 8kg and increasing fatigue. She reports early satiety and occasional epigastric discomfort. Physical examination reveals left supraclavicular lymphadenopathy. Abdominal examination shows mild epigastric tenderness. Blood tests show Hb 98 g/L (normal 115-165), MCV 76 fL (normal 80-100), and albumin 32 g/L (normal 35-50). What is the most appropriate next step in management?
- A. Prescribe oral iron supplementation and review in 4 weeks
- B. Request urgent CT chest, abdomen and pelvis
- C. Arrange routine gastroenterology outpatient referral
- D. Request coeliac serology and review with results
- E. Arrange urgent upper gastrointestinal endoscopy within 2 weeks (Correct Answer)
Explanation: ***Arrange urgent upper gastrointestinal endoscopy within 2 weeks***- The patient presents with **alarm features** for **gastric cancer**, including unintentional weight loss, early satiety, and **iron deficiency anaemia** (low Hb and MCV).- The presence of **Virchow’s node** (left supraclavicular lymphadenopathy) is highly suggestive of metastatic abdominal malignancy, requiring an **Oedophago-Gastro-Duodenoscopy (OGD)** for direct visualization and biopsy.*Prescribe oral iron supplementation and review in 4 weeks*- Treating the **anaemia** without investigating the underlying cause in a patient with **red flag symptoms** is inappropriate and delays cancer diagnosis.- Iron deficiency in an older patient with GI symptoms is considered blood loss from a **malignancy** until proven otherwise.*Request urgent CT chest, abdomen and pelvis*- While CT imaging is essential for **staging** a diagnosed cancer, it is not the primary diagnostic tool for visualizing mucosal lesions in the stomach.- **Endoscopy** remains the gold standard for initial diagnosis as it allows for **histopathological confirmation** via biopsy.*Arrange routine gastroenterology outpatient referral*- A routine referral is unsuitable because the suspected diagnosis is **malignancy**, which requires an **urgent two-week wait (2WW)** pathway to improve outcomes.- Delaying the specialist assessment significantly increases the risk of disease progression and **metastasis**.*Request coeliac serology and review with results*- Although **Coeliac disease** causes malabsorption and weight loss, it does not typically present with **supraclavicular lymphadenopathy** or early satiety.- Investigating for Benign conditions first is a clinical error when the presentation strongly points toward **upper GI malignancy**.
Question 96: A 44-year-old woman presents with a 17-week history of fatigue and generalised pain. She scores 8/10 for pain on average. She reports cognitive difficulties ('brain fog'), poor sleep, and irritable bowel symptoms. Physical examination including joint and neurological assessment is normal. Blood tests including FBC, ESR, CRP, thyroid function, vitamin D, and calcium are normal. She has tried several analgesics without benefit. What is the single most important component of effective management according to current UK guidelines?
- A. Explanation of the condition with emphasis on self-management strategies and validating her symptoms (Correct Answer)
- B. Trial of amitriptyline 10mg at night with review at 4 weeks
- C. Referral to rheumatology for specialist assessment and confirmation of diagnosis
- D. Referral to pain clinic for multidisciplinary pain management programme
- E. Trial of duloxetine 30mg daily with gradual dose escalation
Explanation: ***Explanation of the condition with emphasis on self-management strategies and validating her symptoms*** - The patient's symptoms (widespread pain, fatigue, cognitive difficulties, poor sleep, IBS) with normal investigations are highly consistent with **fibromyalgia**, a form of **chronic primary pain**. - According to **NICE guidelines (NG193)**, the most important initial step is to build a therapeutic relationship, validate the patient's experience, and educate them on **self-management strategies** like physical activity, sleep hygiene, and stress management. *Trial of amitriptyline 10mg at night with review at 4 weeks* - While **amitriptyline** is a recommended pharmacological option for chronic primary pain, it is typically considered *after* non-pharmacological approaches and comprehensive patient education have been established. - Starting medication without first addressing the patient's understanding of their condition and empowering **self-management** is not the primary or most important initial step. *Referral to rheumatology for specialist assessment and confirmation of diagnosis* - **Fibromyalgia** is primarily a **clinical diagnosis** based on history and examination, often manageable in primary care, especially with normal inflammatory markers (ESR, CRP). - **Specialist referral** is usually reserved for diagnostic uncertainty or suspicion of an underlying inflammatory condition not excluded by initial workup. *Referral to pain clinic for multidisciplinary pain management programme* - **Multidisciplinary pain management programmes** are valuable for complex chronic pain, but they are generally for patients who have not responded to initial primary care interventions and self-management. - This is not the
Question 97: A 54-year-old man presents with a 10-week history of pain in his lower back and hips. The pain is worse in the morning, improves with activity, and is associated with stiffness lasting 90 minutes. He wakes at night with pain and stiffness. NSAIDs provide good relief. Examination shows reduced lumbar spine flexion. Blood tests show ESR 58 mm/hr, CRP 42 mg/L, normal FBC and renal function. X-ray of spine and pelvis is reported as normal. What is the most appropriate next investigation?
- A. MRI of sacroiliac joints and spine (Correct Answer)
- B. HLA-B27 testing
- C. Bone scintigraphy (isotope bone scan)
- D. CT of spine and pelvis
- E. Repeat X-ray of sacroiliac joints in 3 months
Explanation: ***MRI of sacroiliac joints and spine*** - MRI is the gold standard for diagnosing **non-radiographic axial spondyloarthritis** as it can detect **bone marrow edema** and active inflammation before structural damage appears on X-rays. - This patient presents with classic **inflammatory back pain** (morning stiffness, improvement with exercise, night pain) and elevated inflammatory markers (ESR, CRP), making MRI the most appropriate next step when X-rays are normal. *HLA-B27 testing* - While **HLA-B27** is associated with axial spondyloarthritis, it is not diagnostic on its own, as it is present in approximately 8% of the healthy population and does not substitute for imaging findings. - A negative result does not rule out the disease, and a positive result without imaging evidence of **sacroiliitis** is insufficient for a definitive diagnosis in this clinical context. *Bone scintigraphy (isotope bone scan)* - This modality is highly **non-specific** for axial spondyloarthritis and often shows increased uptake in any area of high bone turnover or general inflammation. - It lacks the sensitivity and anatomical detail required to visualize the specific **bone marrow edema** characteristic of early inflammatory spinal disease. *CT of spine and pelvis* - CT is excellent for visualizing **structural changes** like erosions or ankylosis but is much less sensitive than MRI for detecting early-stage active inflammation and **soft tissue edema**. - It involves significant **ionizing radiation** without providing the diagnostic benefit of identifying active bone marrow edema, which is crucial in early disease. *Repeat X-ray of sacroiliac joints in 3 months* - **Radiographic changes** (secondary to structural damage) can take years to develop on X-rays, making a 3-month follow-up highly likely to be negative and causing an unnecessary delay in treatment. - Current clinical guidelines recommend escalating to **MRI** immediately if clinical suspicion for inflammatory back pain remains high despite a normal initial X-ray.
Question 98: A 48-year-old man presents with a 15-week history of fatigue, night sweats, and 8kg weight loss. Examination reveals non-tender cervical and axillary lymphadenopathy. Blood tests show Hb 102 g/L, WCC 18.5 × 10⁹/L (lymphocytes 14.2 × 10⁹/L), platelets 145 × 10⁹/L, ESR 45 mm/hr, LDH 520 U/L. Blood film shows mature small lymphocytes with smudge cells. What is the most likely diagnosis?
- A. Hodgkin lymphoma
- B. Chronic lymphocytic leukaemia with Richter transformation
- C. Infectious mononucleosis with atypical lymphocytosis
- D. Chronic lymphocytic leukaemia (Correct Answer)
- E. Non-Hodgkin lymphoma (follicular type)
Explanation: ***Chronic lymphocytic leukaemia*** - The presence of **mature small lymphocytes** and characteristic **smudge cells** (Gumprecht shadows) on the blood film is pathognomonic for **chronic lymphocytic leukaemia (CLL)**. - This patient exhibits a persistent **absolute lymphocytosis** (>5 × 10⁹/L) and clinical features like **lymphadenopathy** and B-symptoms (weight loss, night sweats). *Hodgkin lymphoma* - Typically presents with localized or mediastinal **lymphadenopathy** and lacks the significant **peripheral blood lymphocytosis** seen in this patient. - Diagnosis is confirmed by **lymph node biopsy** identifying **Reed-Sternberg cells**, not by smudge cells on a peripheral film. *Chronic lymphocytic leukaemia with Richter transformation* - **Richter transformation** involves the sudden evolution of CLL into a high-grade **Diffuse Large B-cell Lymphoma**, usually marked by rapidly enlarging nodes and extreme **LDH** elevation. - While this patient has B-symptoms, the blood film still shows **mature small lymphocytes** rather than the large pleomorphic blasts expected in transformation. *Infectious mononucleosis with atypical lymphocytosis* - Infectious mononucleosis typically presents as an **acute** illness (1–2 weeks) with sore throat and fever, whereas this case is **chronic** (15 weeks). - The blood film in mononucleosis shows **atypical lymphocytes** (reactive CD8+ T-cells), which are larger and more irregular than the **smudge cells** seen here. *Non-Hodgkin lymphoma (follicular type)* - Follicular lymphoma usually presents with painless, waxing and waning **lymphadenopathy** but rarely causes significant **peripheral lymphocytosis**. - Diagnosis requires a **node biopsy** showing follicular architecture; it does not produce the characteristic **smudge cells** seen in CLL.
Question 99: A 67-year-old woman presents with a 13-week history of unintentional weight loss (9kg) and progressive fatigue. She has noted increased thirst and urinary frequency. Blood tests show glucose 18.2 mmol/L, HbA1c 72 mmol/mol, C-peptide <50 pmol/L (low), and GAD antibodies strongly positive. She has no personal or family history of autoimmune disease. What is the most appropriate initial management?
- A. Commence metformin 500mg twice daily with lifestyle advice and review in 3 months
- B. Commence basal-bolus insulin regimen with diabetes specialist nurse support (Correct Answer)
- C. Commence once-daily basal insulin with metformin and review in 2 weeks
- D. Arrange urgent hospital admission for management of diabetic ketoacidosis
- E. Commence GLP-1 receptor agonist with SGLT-2 inhibitor combination
Explanation: ***Commence basal-bolus insulin regimen with diabetes specialist nurse support***- The patient presents with clinical features and lab results highly suggestive of **Latent Autoimmune Diabetes in Adults (LADA)**, including **positive GAD antibodies**, a profoundly low **C-peptide**, and significant weight loss, all indicating severe **insulin deficiency**.- A **basal-bolus insulin regimen** is the most appropriate initial management for patients with absolute or near-absolute insulin deficiency, as it provides both foundational (basal) and mealtime (bolus) insulin coverage, crucial for effective glycemic control and symptom resolution.*Commence metformin 500mg twice daily with lifestyle advice and review in 3 months*- **Metformin** works primarily by reducing hepatic glucose production and improving insulin sensitivity, but it is ineffective in cases of severe **insulin deficiency** as seen here with the low C-peptide and positive GAD antibodies.- Relying on oral agents when there is significant beta-cell destruction would lead to persistent hyperglycemia, worsening symptoms, and a potential risk of **diabetic ketoacidosis (DKA)**.*Commence once-daily basal insulin with metformin and review in 2 weeks*- While **basal insulin** is a necessary component, providing *only* basal insulin would be insufficient to manage the post-prandial glucose excursions in a patient with severe **insulin deficiency** and symptomatic hyperglycemia.- **Metformin** offers little to no benefit in this scenario, as the primary problem is lack of insulin, not insulin resistance. A comprehensive insulin regimen is required.*Arrange urgent hospital admission for management of diabetic ketoacidosis*- Although the patient has significant hyperglycemia (glucose 18.2 mmol/L), there is no specific evidence provided in the stem (e.g., low pH, low bicarbonate, high ketones) to confirm **diabetic ketoacidosis (DKA)**.- Given the stable presentation without overt signs of critical illness (like vomiting or altered mental status), initiating appropriate insulin therapy in an **outpatient setting** with close follow-up and specialist support is generally feasible.*Commence GLP-1 receptor agonist with SGLT-2 inhibitor combination*- **GLP-1 receptor agonists** require some residual beta-cell function to stimulate insulin secretion, which is severely compromised in this patient with a low **C-peptide** and **GAD antibodies**.- **SGLT-2 inhibitors** increase the risk of **euglycemic diabetic ketoacidosis**, especially in patients with **Type 1 diabetes** or **LADA** due to severe insulin deficiency, making them a contraindicated or high-risk option.
Question 100: A 55-year-old woman with chronic kidney disease stage 4 presents with worsening fatigue and generalised bone pain over 8 weeks. Blood tests show corrected calcium 2.15 mmol/L, phosphate 1.95 mmol/L, PTH 185 pg/mL (normal 15-65), ALP 245 U/L, and 25-hydroxyvitamin D 22 nmol/L. Hb 96 g/L, ferritin 45 μg/L. Which intervention should be prioritised first?
- A. Commence alfacalcidol and phosphate binders
- B. Arrange for erythropoietin-stimulating agent therapy
- C. Arrange urgent nephrology review for potential parathyroidectomy
- D. Commence colecalciferol supplementation at high dose (Correct Answer)
- E. Commence cinacalcet to reduce PTH levels
Explanation: ***Commence colecalciferol supplementation at high dose*** - The patient has **severe native vitamin D deficiency** (25-hydroxyvitamin D 22 nmol/L) which is a primary driver of her **secondary hyperparathyroidism** and bone pain. - Replenishing **25-hydroxyvitamin D stores** with **colecalciferol** is the initial step to naturally lower **PTH** and improve bone mineralisation, often preceding active vitamin D analogues. *Commence alfacalcidol and phosphate binders* - **Alfacalcidol**, an active vitamin D analogue, should generally not be initiated before correcting **severe native vitamin D deficiency** to avoid potential hypercalcemia and ensure proper overall vitamin D metabolism. - While **phosphate binders** are indicated for hyperphosphatemia, addressing the severe vitamin D deficiency is the more immediate and foundational step in managing the overall CKD-MBD picture. *Arrange for erythropoietin-stimulating agent therapy* - The patient's **anemia** (Hb 96 g/L) needs evaluation, but her **ferritin** of 45 μg/L suggests potential **iron deficiency**, which should be treated before considering an **ESA**. - This intervention primarily targets anemia and does not directly address the severe **bone pain** or the underlying **CKD-MBD** pathophysiology. *Arrange urgent nephrology review for potential parathyroidectomy* - **Parathyroidectomy** is a treatment for **refractory secondary hyperparathyroidism** or tertiary hyperparathyroidism, typically after medical management has failed. - Given the severe, uncorrected **vitamin D deficiency**, medical therapy is highly likely to be effective and should be exhausted first, making surgery not an urgent first priority. *Commence cinacalcet to reduce PTH levels* - **Cinacalcet** (a calcimimetic) is typically used for uncontrolled **secondary hyperparathyroidism** in dialysis patients or when PTH remains high despite optimal vitamin D and phosphate management. - It is not a first-line treatment when there is an uncorrected, severe **native vitamin D deficiency**, which needs to be addressed first.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free